https://www.pharmaradar360.com/article/drug-label-update-loperamide-hydrochloride-34f527e2a863fad9Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: Loperamide Hydrochloridehttps://www.pharmaradar360.com/article/drug-label-update-nystatin-c4a3e9d3e9bda5e6Pharma Surgeen2026-06-30T00:00:00.000ZDrug label update: NYSTATINhttps://www.pharmaradar360.com/article/dianthus-launches-phase-3-trial-for-myasthenia-gravis-treatment-by-investing-com-e46d07b56bcd00e4Pharma Surgeen2026-06-29T11:19:02.000ZDianthus launches phase 3 trial for myasthenia gravis treatment By Investing.comhttps://www.pharmaradar360.com/article/zymeworks-to-acquire-troubled-biotech-theravance-in-929m-deal-6177903a8069bc31Pharma Surgeen2026-06-29T11:13:00.000ZZymeworks to acquire troubled biotech Theravance in $929M dealhttps://www.pharmaradar360.com/article/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-of-clasepruba-a2313cd11db1a046Pharma Surgeen2026-06-29T11:03:46.000ZDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravishttps://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-7bbe0add77b9e3d5Pharma Surgeen2026-06-29T11:03:43.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2025https://www.pharmaradar360.com/article/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes-76a3fde067523072Pharma Surgeen2026-06-29T11:00:00.000ZRelmada Therapeutics Joins Russell 2000® and Russell 3000® Indexeshttps://www.pharmaradar360.com/article/dianthus-launches-phase-3-study-of-claseprubart-in-rare-muscle-disease-c1cf30d5729c8a9fPharma Surgeen2026-06-29T11:00:00.000ZDianthus launches Phase 3 study of claseprubart in rare muscle diseasehttps://www.pharmaradar360.com/article/artivion-s-amds-gets-fda-approval-for-deadly-aortic-tears-638efc8e60572ad1Pharma Surgeen2026-06-29T11:00:00.000ZArtivion’s AMDS gets FDA approval for deadly aortic tearshttps://www.pharmaradar360.com/article/viatris-kidney-drug-vr-205-cut-protein-in-urine-33-75-in-japan-f350fde4db904741Pharma Surgeen2026-06-29T10:59:00.000ZViatris kidney drug VR-205 cut protein in urine 33.75% in Japanhttps://www.pharmaradar360.com/article/biogen-trims-apellis-pipeline-and-r-d-team-after-5-6bn-takeover-707583c43dca7834Pharma Surgeen2026-06-29T10:56:52.000ZBiogen trims Apellis pipeline and R&D team after $5.6bn takeoverhttps://www.pharmaradar360.com/article/merck-announces-new-agreement-with-adap-crisis-task-force-to-improve-access-and-e81dca8917a0fe29Pharma Surgeen2026-06-29T10:45:00.000ZMerck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIVhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-nasdaqgs-rare-added-to-russell-2000-growth-benchma-f8932af55bfd32e2Pharma Surgeen2026-06-29T10:41:59.000ZUltragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmarkhttps://www.pharmaradar360.com/article/aspen-api-was-pleased-to-participate-in-tides-us-2026-in-boston-in-may-8bbea61bb78de835Pharma Surgeen2026-06-29T10:36:25.000ZAspen API was pleased to participate in TIDES US 2026 in Boston in Mayhttps://www.pharmaradar360.com/article/larimar-says-fda-can-review-nomlabofusp-for-accelerated-approval-d145ee221aa98021Pharma Surgeen2026-06-29T10:30:00.000ZLarimar says FDA can review nomlabofusp for accelerated approvalhttps://www.pharmaradar360.com/article/natera-partners-with-aveta-for-phase-3-head-and-neck-cancer-trial-518d8183a0ff70caPharma Surgeen2026-06-29T10:27:32.000ZNatera partners with Aveta for phase 3 head and neck cancer trialhttps://www.pharmaradar360.com/article/are-you-running-clinical-trials-you-can-now-activate-e-mail-notifications-in-cti-12499280f8872d30Pharma Surgeen2026-06-29T10:27:00.000ZAre you running clinical trials? You can now activate e-mail notifications in CTIShttps://www.pharmaradar360.com/article/sandoz-submits-generic-obesity-drug-applications-to-fda-by-investing-com-abc64dfcc2998b2ePharma Surgeen2026-06-29T10:16:00.000ZSandoz submits generic obesity drug applications to FDA By Investing.comhttps://www.pharmaradar360.com/article/building-an-ai-native-pharmaceutical-enterprise-lupin-s-blueprint-for-intelligen-ca5ea977d5f36000Pharma Surgeen2026-06-29T10:10:33.000ZBuilding an AI-native pharmaceutical enterprise: Lupin’s blueprint for intelligent transformation - Lupin | Perspectivehttps://www.pharmaradar360.com/article/fda-clears-pen-device-for-interferon-therapy-in-polycythemia-vera-eb22487b97a4bbe7Pharma Surgeen2026-06-29T10:07:29.000ZFDA Clears Pen Device for Interferon Therapy in Polycythemia Verahttps://www.pharmaradar360.com/article/goldenwell-biotech-gwll-restates-q3-2025-and-flags-going-concern-99e79c5cc49bd449Pharma Surgeen2026-06-29T10:04:18.000ZGoldenwell Biotech (GWLL) restates Q3 2025 and flags going concernhttps://www.pharmaradar360.com/article/zymeworks-to-acquire-theravance-biopharma-inc-fd4d8568322bafcbPharma Surgeen2026-06-29T10:01:22.000ZZymeworks to Acquire Theravance Biopharma, Inc.https://www.pharmaradar360.com/article/class-4-medicines-defect-notification-brancaster-pharma-limited-benzylpenicillin-f6e60c5adaa15ef5Pharma Surgeen2026-06-29T10:00:30.000ZClass 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30https://www.pharmaradar360.com/article/97-62c242051db53da6Pharma Surgeen2026-06-29T10:00:00.000Z日本新薬硬式野球部「第97回 都市対抗野球大会」に京都市代表として出場決定https://www.pharmaradar360.com/article/natera-joins-aveta-s-global-phase-3-head-and-neck-cancer-trial-37b8b133c9687a49Pharma Surgeen2026-06-29T10:00:00.000ZNatera joins Aveta's global Phase 3 head and neck cancer trialhttps://www.pharmaradar360.com/article/thai-fda-and-us-officials-convene-to-tighten-pesticide-checks-on-imported-produc-b9ffa5a6efc4a0ddPharma Surgeen2026-06-29T09:55:00.000ZThai FDA and US Officials Convene to Tighten Pesticide Checks on Imported Producehttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-27-report-data-to-week-26-dat-d3a0d7bfc7b6a338Pharma Surgeen2026-06-29T09:50:54.000ZNational flu and COVID-19 surveillance report, week 27 report: data to week 26 (data up to 28 June 2026)https://www.pharmaradar360.com/article/china-emerging-a-global-leader-in-biotech-business-5c4fd427181a9709Pharma Surgeen2026-06-29T09:41:47.000ZChina ‘emerging a global leader’ in biotech businesshttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-c40ee43363d9a479Pharma Surgeen2026-06-29T09:41:42.000ZMeningococcal B (MenB) time limited vaccination offerhttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-information-for-healthcare-p-a9d27fb6d5e14baePharma Surgeen2026-06-29T09:41:39.000ZMeningococcal B (MenB) time limited vaccination offer: information for healthcare practitionershttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-31-report-data-to-week-30-dat-a3fb4f87cd2afcf2Pharma Surgeen2026-06-29T09:37:23.000ZNational flu and COVID-19 surveillance report, week 31 report: data to week 30 (data up to 26 July 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-26-july-2026-e8a5763a98861b0ePharma Surgeen2026-06-29T09:37:12.000ZWeekly all-cause mortality surveillance: week ending 26 July 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-31-report-data-to-week-30-26-july-2-382af7c5ca707f23Pharma Surgeen2026-06-29T09:37:03.000ZNational Norovirus and Rotavirus Report, week 31 report: data to week 30 (26 July 2026)https://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-report-q2-2026-7c808e6c9251c844Pharma Surgeen2026-06-29T09:36:54.000ZTuberculosis in England national quarterly report: Q2 2026https://www.pharmaradar360.com/article/fda-set-to-review-sandoz-s-generic-glp-1s-8a1d0a8a27a6c458Pharma Surgeen2026-06-29T09:33:43.000ZFDA set to review Sandoz's generic GLP-1shttps://www.pharmaradar360.com/article/biotech-investor-pumps-the-brakes-on-ai-drug-discovery-88d76ca530f3fd4cPharma Surgeen2026-06-29T09:30:00.000ZBiotech Investor Pumps the Brakes on AI Drug Discoveryhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kubota-pharmaceutical-holdings-co-ltd-tse-7e409513fcbca4cfPharma Surgeen2026-06-29T09:22:00.000ZEnterprise value to revenue forward of Kubota Pharmaceutical Holdings Co. Ltd. – TSE:4596https://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-c236f2e8484f9816Pharma Surgeen2026-06-29T09:21:17.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/shiga-toxin-producing-escherichia-coli-how-to-avoid-and-treat-005c4cafd7701d69Pharma Surgeen2026-06-29T09:18:19.000ZShiga toxin-producing Escherichia coli: how to avoid and treathttps://www.pharmaradar360.com/article/regulatory-round-up-29-june-2026-5766f4452813c0e6Pharma Surgeen2026-06-29T09:17:59.000ZRegulatory round-up: 29 June 2026https://www.pharmaradar360.com/article/us-texas-biotech-firm-to-build-noah-s-ark-for-endangered-species-fd6262a7ebfd0245Pharma Surgeen2026-06-29T09:17:54.000ZUS, Texas biotech firm to build 'Noah's Ark' for endangered specieshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-shaanxi-micot-pharmaceutical-technology-co-a3cd4c8590176ce4Pharma Surgeen2026-06-29T09:14:18.000ZEnterprise value to EBITDA forward of Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H – HKEX:2335https://www.pharmaradar360.com/article/fda-issues-complete-response-letter-to-sobi-s-nasp-for-gout-a6241daad60686edPharma Surgeen2026-06-29T09:10:50.000ZFDA issues complete response letter to Sobi’s NASP for gouthttps://www.pharmaradar360.com/article/ever-supreme-launches-phase-iia-clinical-trial-for-car001-accelerating-global-ma-a9a562bafcc575a0Pharma Surgeen2026-06-29T09:09:05.000ZEver Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansionhttps://www.pharmaradar360.com/article/ema-recommends-approval-of-hopledo-for-parkinson-s-disease-4d70e6bcab6c9805Pharma Surgeen2026-06-29T09:05:20.000ZEMA Recommends Approval of Hopledo for Parkinson's Diseasehttps://www.pharmaradar360.com/article/dhsc-evaluation-strategy-2026-e8e86cb6f5db9997Pharma Surgeen2026-06-29T09:00:01.000ZDHSC evaluation strategy 2026https://www.pharmaradar360.com/article/samsung-bioepis-announced-on-the-29th-that-it-proved-its-equivalence-with-the-or-2c5856e5a312f251Pharma Surgeen2026-06-29T08:52:25.000ZSamsung Bioepis announced on the 29th that it proved its equivalence with the original drug in eachhttps://www.pharmaradar360.com/article/abbvie-receives-positive-chmp-opinion-for-upadacitinib-for-the-treatment-of-adul-e45ab85080f951f1Pharma Surgeen2026-06-29T08:49:00.000ZAbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/nearly-400-antibiotic-resistant-infections-each-week-in-2024-bc908d04a513c635Pharma Surgeen2026-06-29T08:41:15.000ZNearly 400 antibiotic-resistant infections each week in 2024https://www.pharmaradar360.com/article/the-u-s-china-biotech-crackdown-may-hurt-the-scientists-america-needs-the-most-f89110c4fc3c0204Pharma Surgeen2026-06-29T08:31:07.000ZThe U.S.-China biotech crackdown may hurt the scientists America needs the mosthttps://www.pharmaradar360.com/article/xerafy-smart-rfid-label-for-healthcare-and-pharmaceutical-packagi-c14bf6607a360efbPharma Surgeen2026-06-29T08:24:55.000ZXerafy Smart RFID Label for Healthcare and Pharmaceutical Packagihttps://www.pharmaradar360.com/article/5-biotech-stocks-that-skyrocketed-105-to-235-twst-indv-mirm-more-c07d9568bbe44f74Pharma Surgeen2026-06-29T08:18:00.000Z5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & Morehttps://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-d604fc61f0bdb53ePharma Surgeen2026-06-29T08:15:43.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/seers-wins-fda-510-k-for-mobicare-speeds-push-into-us-medicare-market-chosunbiz-67c32bb90bf9bc39Pharma Surgeen2026-06-29T08:14:00.000ZSeers wins FDA 510(k) for mobiCARE, speeds push into US Medicare market - CHOSUNBIZhttps://www.pharmaradar360.com/article/french-biotech-company-ipsen-to-buy-kartos-therapeutics-for-450-million-da0440d7131f9c4fPharma Surgeen2026-06-29T08:11:15.000ZFrench biotech company Ipsen to buy Kartos Therapeutics for $450 millionhttps://www.pharmaradar360.com/article/telitacicept-improves-clinical-response-but-increases-infection-and-hypogammaglo-0e03eede59c1bebcPharma Surgeen2026-06-29T08:08:51.000ZTelitacicept Improves Clinical Response but Increases Infection and Hypogammaglobulinemia Risk in Adults with Active SLE: Phase 3 Trial Resultshttps://www.pharmaradar360.com/article/biovitrum-falls-3-after-fda-declines-approval-for-gout-therapy-by-investing-com-f1536857f07d0287Pharma Surgeen2026-06-29T08:08:42.000ZBiovitrum falls 3% after FDA declines approval for gout therapy By Investing.comhttps://www.pharmaradar360.com/article/biotech-veterans-aim-to-build-startups-from-the-ground-up-at-capehaven-cc4f29ef7d5a5999Pharma Surgeen2026-06-29T08:00:49.000ZBiotech veterans aim to build startups from the ground up at CapeHavenhttps://www.pharmaradar360.com/article/china-closing-in-but-us-leads-in-biotech-quality-commercial-reach-survey-finds-7a29f870165688e5Pharma Surgeen2026-06-29T08:00:00.000ZChina closing in but US leads in biotech quality, commercial reach, survey findshttps://www.pharmaradar360.com/article/abbvie-broadens-immunology-focus-with-10-9-billion-apogee-deal-2034f7f44469a4b8Pharma Surgeen2026-06-29T08:00:00.000ZAbbVie broadens immunology focus with $10.9 billion Apogee dealhttps://www.pharmaradar360.com/article/target-trial-emulation-using-french-ms-registry-data-replicated-rct-treatment-ef-055b90da33ccbf00Pharma Surgeen2026-06-29T07:43:24.000ZTarget trial emulation using French MS registry data replicated RCT treatment effects on relapse rate and EDSS progression, but not consistently on MRI outcomes, in patients with multiple sclerosis initiating disease-modifying therapieshttps://www.pharmaradar360.com/article/bio-usa-2026-galux-pushes-ai-protein-design-toward-bigger-global-pharma-deals-c9115584db8c308bPharma Surgeen2026-06-29T07:41:38.000Z[BIO USA 2026] Galux pushes AI protein design toward bigger global pharma dealshttps://www.pharmaradar360.com/article/samsung-bioepis-demonstrates-equivalence-in-phase-1-and-3-trials-of-keytruda-bio-c48435a97e714463Pharma Surgeen2026-06-29T07:37:41.000ZSamsung Bioepis Demonstrates Equivalence in Phase 1 and 3 Trials of Keytruda Biosimilarhttps://www.pharmaradar360.com/article/samsung-bioepis-announces-positive-preliminary-phase-1-and-phase-3-data-for-sb27-75c1d3b49b057566Pharma Surgeen2026-06-29T07:36:44.000ZSamsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab) – News Hubhttps://www.pharmaradar360.com/article/mdd-class-ii-hybrid-guidewire-fa122de36442cd71Pharma Surgeen2026-06-29T07:35:13.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIΙ, HYBRID Guidewirehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-vytrus-biotech-sa-bme-vyt-6a6429a317286a00Pharma Surgeen2026-06-29T07:22:26.000ZEnterprise value to EBIT forward of Vytrus Biotech SA – BME:VYThttps://www.pharmaradar360.com/article/swiss-pharma-at-risk-of-us-trade-investigation-industry-body-says-5e2839a6649fa359Pharma Surgeen2026-06-29T07:22:20.000ZSwiss pharma at risk of US trade investigation, industry body sayshttps://www.pharmaradar360.com/article/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-930a6b4ba0e326a1Pharma Surgeen2026-06-29T07:10:00.000ZAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/the-global-push-to-reduce-animal-testing-in-drug-development-8afd5b2c2daecdcaPharma Surgeen2026-06-29T07:05:12.000ZThe global push to reduce animal testing in drug developmenthttps://www.pharmaradar360.com/article/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-23135c16d763494cPharma Surgeen2026-06-29T07:00:00.000ZAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligohttps://www.pharmaradar360.com/article/zambon-and-amneal-announce-positive-chmp-opinion-for-hopledo-ipx203-for-adults-w-b03eeb2074a19526Pharma Surgeen2026-06-29T07:00:00.000ZZambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuationshttps://www.pharmaradar360.com/article/infigratinib-shows-2-1-cm-year-height-gain-in-achondroplasia-trial-b3a09db71d87f633Pharma Surgeen2026-06-29T06:48:08.000ZInfigratinib Shows +2.1 cm/year Height Gain in Achondroplasia Trialhttps://www.pharmaradar360.com/article/etfs-investing-in-shanghai-micurx-pharmaceutical-co-ltd-class-a-stocks-f33f8815c61b6f92Pharma Surgeen2026-06-29T06:43:15.000ZETFs Investing in Shanghai MicuRx Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/haisco-pharmaceutical-group-co-ltd-class-a-actuals-estimates-szse-002653-6fe22a422fee619ePharma Surgeen2026-06-29T06:37:04.000ZHaisco Pharmaceutical Group Co. Ltd. Class A Actuals & Estimates (SZSE:002653)https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-kane-biotech-inc-tsxv-kne-5e2d9911ebfb5b04Pharma Surgeen2026-06-29T06:09:18.000ZEnterprise value to EBITDA forward of Kane Biotech Inc. – TSXV:KNEhttps://www.pharmaradar360.com/article/last-week-in-review-374e9b49d21e40efPharma Surgeen2026-06-29T05:24:09.000ZLAST WEEK IN REVIEWhttps://www.pharmaradar360.com/article/lecanemab-alzheimer-s-drug-shows-limited-benefit-experts-urge-cautious-use-f2a96b800fd9002ePharma Surgeen2026-06-29T05:06:00.000ZLecanemab Alzheimer’s drug shows limited benefit, experts urge cautious usehttps://www.pharmaradar360.com/article/roche-announces-the-launch-of-axelios-1-a-transformative-next-generation-sequenc-73de3f3a61c17897Pharma Surgeen2026-06-29T05:00:00.000ZRoche announces the launch of AXELIOS 1, a transformative next-generation sequencing platformhttps://www.pharmaradar360.com/article/aribio-completes-main-phase-3-dosing-for-oral-alzheimer-s-drug-ar1001-topline-da-d2f56910e7924a13Pharma Surgeen2026-06-29T04:48:56.000ZAriBio completes main phase 3 dosing for oral Alzheimer's drug AR1001, topline data due this fallhttps://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998Pharma Surgeen2026-06-29T04:26:48.000ZSLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncologyhttps://www.pharmaradar360.com/article/gc-wellbeing-secures-korean-rights-to-next-gen-fat-dissolving-injection-ahead-of-10f2843623db7795Pharma Surgeen2026-06-29T04:25:02.000ZGC Wellbeing secures Korean rights to next-gen fat-dissolving injection ahead of US phase 3 trialhttps://www.pharmaradar360.com/article/china-s-burgeoning-biopharmaceutical-competitiveness-demands-a-us-response-repor-0cba935ea96ccef6Pharma Surgeen2026-06-29T04:05:07.000ZChina’s Burgeoning Biopharmaceutical Competitiveness Demands a US Response | Reports & Briefings | Jun 29, 2026https://www.pharmaradar360.com/article/inside-lilly-s-biotech-startup-factory-eae069b2732e19a9Pharma Surgeen2026-06-29T03:57:43.000ZInside Lilly's biotech startup factoryhttps://www.pharmaradar360.com/article/sk-chemicals-j2h-biotech-sign-loi-to-co-develop-mash-therapy-7e391c8ca0f64240Pharma Surgeen2026-06-29T03:28:15.000ZSK chemicals, J2H Biotech sign LOI to co-develop MASH therapyhttps://www.pharmaradar360.com/article/shinsa-information-regarding-explanations-to-driver-mutations-in-the-development-6e813271093e8f27Pharma Surgeen2026-06-29T03:00:00.000Z[SHINSA]Information Regarding Explanations to Driver Mutations in the Development of Anti-cancer Drugs（Early Consideration）posted.https://www.pharmaradar360.com/article/price-to-book-forward-of-burning-rock-biotech-ltd-sponsored-adr-dus-6bu0-c933e936b17b5dcePharma Surgeen2026-06-29T02:57:41.000ZPrice to book forward of Burning Rock Biotech Ltd. Sponsored ADR – DUS:6BU0https://www.pharmaradar360.com/article/how-a-regional-pharmaceutical-leader-maintained-compliance-through-divestiture-w-508dbf48f3250db6Pharma Surgeen2026-06-29T02:39:37.000ZHow A Regional Pharmaceutical Leader Maintained Compliance Through Divestiture Without Disrupting Operationshttps://www.pharmaradar360.com/article/star-therapeutics-to-present-complete-data-from-phase-1-2-multidose-study-of-vga-34fb314ef4ca0d8aPharma Surgeen2026-06-29T02:20:52.000ZStar Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congresshttps://www.pharmaradar360.com/article/interview-biotech-act-rapporteur-defends-evidence-first-approach-to-spc-debate-29003b347e33c750Pharma Surgeen2026-06-29T02:14:56.000ZINTERVIEW: Biotech Act rapporteur defends evidence-first approach to SPC debatehttps://www.pharmaradar360.com/article/etfs-investing-in-binh-dinh-pharmaceutical-medical-equipment-jsc-stocks-1e39be3fd72fd6c3Pharma Surgeen2026-06-29T02:12:43.000ZETFs Investing in Binh Dinh Pharmaceutical & Medical Equipment JSC Stockshttps://www.pharmaradar360.com/article/autotelic-bio-wins-fda-approval-for-atb-101-phase-1-trial-in-us-88621b2b8148e088Pharma Surgeen2026-06-29T02:05:44.000ZAutotelic Bio Wins FDA Approval for ATB-101 Phase 1 Trial in UShttps://www.pharmaradar360.com/article/gc-wellbeing-secures-rights-to-next-gen-fat-dissolving-injection-f70810f79c57b5b2Pharma Surgeen2026-06-29T01:55:19.000ZGC Wellbeing secures rights to next-gen fat-dissolving injectionhttps://www.pharmaradar360.com/article/csl-halts-tavneos-drug-sale-following-eu-regulatory-setback-50c24fe8aa2f4bacPharma Surgeen2026-06-29T01:54:00.000ZCSL halts Tavneos drug sale following EU regulatory setbackhttps://www.pharmaradar360.com/article/lupin-receives-tentative-approval-from-u-s-fda-for-enzalutamide-tablets-696686ad9d3f3954Pharma Surgeen2026-06-29T01:34:33.000ZLupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tabletshttps://www.pharmaradar360.com/article/poland-calls-for-unified-eu-strategy-on-biotech-and-critical-medicines-49ee9567e12dd19ePharma Surgeen2026-06-29T01:04:55.000ZPoland calls for unified EU strategy on biotech and critical medicineshttps://www.pharmaradar360.com/article/news-biotech-job-funding-growth-signal-rising-space-demand-mortgage-applications-51fe1d7b26279ec7Pharma Surgeen2026-06-29T01:00:23.000ZNews | Biotech job, funding growth signal rising space demand; Mortgage applications increase; Construction employment slowshttps://www.pharmaradar360.com/article/joint-research-with-tohoku-universityestablishment-of-a-collaborative-research-p-e30c5425535caecePharma Surgeen2026-06-29T01:00:00.000ZJoint Research with Tohoku UniversityEstablishment of a Collaborative Research Program on Water Turnover and Total Conditioninghttps://www.pharmaradar360.com/article/ellagic-acid-market-forecast-points-higher-toward-2035-driven-by-pharmaceutical-5a942848908492b0Pharma Surgeen2026-06-29T00:36:34.000ZEllagic Acid Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical and Bioprocessing Demandhttps://www.pharmaradar360.com/article/aribio-completes-patient-dosing-in-global-phase-3-trial-of-oral-alzheimer-s-drug-cc4248343c9653c4Pharma Surgeen2026-06-29T00:22:54.000ZAriBio Completes Patient Dosing in Global Phase 3 Trial of Oral Alzheimer's Drughttps://www.pharmaradar360.com/article/aribio-completes-global-phase-3-trials-for-oral-alzheimers-drug-ar1001-6784ea213a2ac52bPharma Surgeen2026-06-29T00:20:00.000ZAribio Completes Global Phase 3 Trials for Oral Alzheimers Drug AR1001https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-e02d426260ca6839Pharma Surgeen2026-06-29T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-06-29T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dac4bd80d7c8b8acPharma Surgeen2026-06-29T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-af6f730bddf8b15cPharma Surgeen2026-06-29T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-2f81d72aeda757afPharma Surgeen2026-06-29T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-7218f0fce9bb4b35Pharma Surgeen2026-06-29T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a56fc9ffdfd43cafPharma Surgeen2026-06-29T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1386550ec89e33afPharma Surgeen2026-06-29T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e687ded803cffb28Pharma Surgeen2026-06-29T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-bf04d3f53448505dPharma Surgeen2026-06-29T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-a8eb9db27b332a32Pharma Surgeen2026-06-29T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-205be3b6295090d1Pharma Surgeen2026-06-29T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-83766fe81e3f3700Pharma Surgeen2026-06-29T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-56d3862721574f4aPharma Surgeen2026-06-29T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-27603280f3fda9e4Pharma Surgeen2026-06-29T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-a7c89ae8df1d2332Pharma Surgeen2026-06-29T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicaid-program-community-engagement-requirement-for-certain-individuals-1d26d189434b3bfePharma Surgeen2026-06-29T00:00:00.000ZMedicaid Program; Community Engagement Requirement for Certain Individualshttps://www.pharmaradar360.com/article/medical-devices-orthopedic-devices-classification-of-the-medial-knee-implanted-s-fd100919342a44b7Pharma Surgeen2026-06-29T00:00:00.000ZMedical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorberhttps://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establis-294eb2e757dd644ePharma Surgeen2026-06-29T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-d5bbe70ce274cde2Pharma Surgeen2026-06-29T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-1d3e91a0a7e5b991Pharma Surgeen2026-06-29T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Rural Health Care Coordination Program Performance Improvement Measures, OMB No. 0906-0024-Revisionhttps://www.pharmaradar360.com/article/advisory-committee-on-breast-cancer-in-young-women-notice-of-charter-renewal-0634329210e3cc44Pharma Surgeen2026-06-29T00:00:00.000ZAdvisory Committee on Breast Cancer in Young Women; Notice of Charter Renewalhttps://www.pharmaradar360.com/article/establishment-registration-and-product-listing-for-tobacco-products-6e6b342c075c962aPharma Surgeen2026-06-29T00:00:00.000ZEstablishment Registration and Product Listing for Tobacco Productshttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-closed-meeting-46b7ba8a4b47d3b3Pharma Surgeen2026-06-29T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyale-8ca1eed56c7ae4d1Pharma Surgeen2026-06-29T00:00:00.000ZDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEVhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-bc4ab3d843985ba0Pharma Surgeen2026-06-29T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Specieshttps://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-closed-meeting-21960810b2679d58Pharma Surgeen2026-06-29T00:00:00.000ZNational Heart, Lung, and Blood Institute; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-6029d027a108b490Pharma Surgeen2026-06-29T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-425f2800aae3c69bPharma Surgeen2026-06-29T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-fda-approval-of-the-lungfxtm-device-fo-66b56bf06da7b7abPharma Surgeen2026-06-29T00:00:00.000ZUnited Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusionhttps://www.pharmaradar360.com/article/build-confidence-in-your-ability-to-get-drug-calculations-right-8268c69bff92193fPharma Surgeen2026-06-29T00:00:00.000ZBuild confidence in your ability to get drug calculations righthttps://www.pharmaradar360.com/article/association-of-periodontitis-severity-and-tooth-loss-with-gastric-cancer-5e0c45e3fad951fbPharma Surgeen2026-06-29T00:00:00.000ZAssociation of periodontitis severity and tooth loss with gastric cancerhttps://www.pharmaradar360.com/article/machine-perfusion-distribution-across-clinical-phenotypes-in-kidney-transplantat-e563b24d2332a2a9Pharma Surgeen2026-06-29T00:00:00.000ZMachine perfusion distribution across clinical phenotypes in kidney transplantation: A national cohort study using unsupervised clusteringhttps://www.pharmaradar360.com/article/occupational-stress-glossophobia-and-impostor-cognitions-an-integrative-clinical-16ea408d30aba3b8Pharma Surgeen2026-06-29T00:00:00.000ZOccupational stress, Glossophobia, and Impostor Cognitions: An Integrative Clinical Case Study of Anxiety and Maladaptive Psychotropic Copinghttps://www.pharmaradar360.com/article/protective-effects-of-tricin-against-oxldl-stimulated-inflammatory-and-oxidative-b9f5132110d402ddPharma Surgeen2026-06-29T00:00:00.000ZProtective Effects of Tricin Against Oxldl-Stimulated Inflammatory and Oxidative Stress Responses in RAW 264.7 Cellshttps://www.pharmaradar360.com/article/time-to-complete-clinical-recovery-and-its-predictors-in-bell-s-palsy-patients-r-b39279aea22e9c79Pharma Surgeen2026-06-29T00:00:00.000ZTime to Complete Clinical Recovery and Its Predictors in Bell’s Palsy Patients Receiving Acupuncture: A Prospective Cohort Studyhttps://www.pharmaradar360.com/article/systematic-review-and-single-arm-meta-analysis-of-the-clinical-value-of-multidis-4faa6c6d5122fde8Pharma Surgeen2026-06-29T00:00:00.000ZSystematic review and single-arm meta-analysis of the clinical value of multidisciplinary team-based multimodal interventions in pulmonary nodule managementhttps://www.pharmaradar360.com/article/brca1-2-pathogenic-variants-in-a-turkish-cohort-clinical-spectrum-novel-truncati-02a0f3583716576fPharma Surgeen2026-06-29T00:00:00.000ZBRCA1/2 Pathogenic Variants in a Turkish Cohort: Clinical Spectrum, Novel Truncating Variants, and Non-Canonical Cancers in the Aegean Regionhttps://www.pharmaradar360.com/article/the-relationship-between-cancer-worry-and-gynecological-cancer-awareness-in-wome-edf272e262648647Pharma Surgeen2026-06-29T00:00:00.000ZThe Relationship Between Cancer Worry and Gynecological Cancer Awareness in Women and Affecting Factorshttps://www.pharmaradar360.com/article/assessment-of-the-current-dental-condition-and-treatment-needs-of-permanent-firs-251d8af80c5146c5Pharma Surgeen2026-06-29T00:00:00.000ZAssessment of the Current Dental Condition and Treatment Needs of Permanent First Molars in University Studentshttps://www.pharmaradar360.com/article/social-media-usage-resilience-and-coping-strategies-in-young-adults-a-multidimen-21bf3da52142208dPharma Surgeen2026-06-29T00:00:00.000ZSocial Media Usage, Resilience, and Coping Strategies in Young Adults: A Multidimensional Analysishttps://www.pharmaradar360.com/article/histopathological-determinants-of-recurrence-in-odontogenic-cysts-and-tumors-imp-33ad15623571de82Pharma Surgeen2026-06-29T00:00:00.000ZHistopathological Determinants of Recurrence in Odontogenic Cysts and Tumors: Implications for Surgical Decision-Making: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/community-pharmacists-perspectives-and-practices-on-antimicrobial-drug-use-and-r-1c90166ea26c7f24Pharma Surgeen2026-06-29T00:00:00.000ZCommunity Pharmacists' Perspectives and Practices on Antimicrobial Drug Use and Resistance: An Educational Intervention Studyhttps://www.pharmaradar360.com/article/the-accuracy-of-ai-based-chatbots-in-responding-to-routinely-asked-questions-abo-d6de07830bc0f4c3Pharma Surgeen2026-06-29T00:00:00.000ZTHE ACCURACY OF AI-BASED CHATBOTS IN RESPONDING TO ROUTINELY ASKED QUESTIONS ABOUT ORTHODONTICS: A COMPARATIVE STUDYhttps://www.pharmaradar360.com/article/awareness-and-utilisation-of-balance-assessment-tools-among-budding-physiotherap-cba635f21597f88dPharma Surgeen2026-06-29T00:00:00.000ZAwareness and Utilisation of Balance Assessment Tools Among Budding Physiotherapists for Identifying Multisensory Integration Deficits and Their Correlation with Fall Risk: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/a-study-of-clinical-profile-of-gall-stone-induced-pancreatitis-and-its-correlati-17707409caeecbcbPharma Surgeen2026-06-29T00:00:00.000ZA Study of Clinical Profile of Gall Stone Induced Pancreatitis and Its Correlation with Severity Indiceshttps://www.pharmaradar360.com/article/physiotherapy-management-of-post-operative-cellulitis-for-functional-recovery-a-c9433bcd8d2e5ddaPharma Surgeen2026-06-29T00:00:00.000ZPhysiotherapy Management of Post-Operative Cellulitis for Functional Recovery: A Case Reporthttps://www.pharmaradar360.com/article/a-study-to-assess-the-effectiveness-of-structured-teaching-programme-on-knowledg-dd6babcf58a69d99Pharma Surgeen2026-06-29T00:00:00.000ZA Study To Assess The Effectiveness of Structured Teaching Programme on Knowledge Regarding Warning Signs of Pregnancy and Its Management Among Primigravida Mother's Attending Antenatal OPD and Obs Ward at SRM MCH and RChttps://www.pharmaradar360.com/article/mitigating-freeze-thaw-and-agitation-induced-particulate-matter-formation-challe-2dffa55d49940622Pharma Surgeen2026-06-29T00:00:00.000ZMitigating Freeze-Thaw and Agitation Induced Particulate Matter Formation Challenge in Biopharmaceuticals: Formulation Strategies and Stability Assessmenthttps://www.pharmaradar360.com/article/rational-design-and-synthesis-of-covalent-krasg12c-inhibitors-as-potential-antic-2cf1b18e032c314bPharma Surgeen2026-06-29T00:00:00.000ZRational Design and Synthesis of Covalent KRASG12C Inhibitors as Potential Anticancer Agentshttps://www.pharmaradar360.com/article/preferred-modalities-on-prevention-and-management-of-iatrogenic-effects-of-ortho-ba3fb42733537873Pharma Surgeen2026-06-29T00:00:00.000ZPreferred Modalities on Prevention and Management of Iatrogenic Effects of Orthodontic Therapy Among Orthodontistshttps://www.pharmaradar360.com/article/clinical-characteristics-and-platelet-related-predictors-of-mortality-in-patient-cc6287207f9295f3Pharma Surgeen2026-06-29T00:00:00.000ZClinical Characteristics and Platelet‑Related Predictors of Mortality in Patients With Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/from-startups-to-giants-leveraging-artificial-intelligence-for-sustainable-innov-ce9fb3c947b8d9acPharma Surgeen2026-06-29T00:00:00.000ZFrom Startups to Giants: Leveraging Artificial Intelligence for Sustainable Innovation and Competitive Advantage in Pharmaceutical Marketinghttps://www.pharmaradar360.com/article/navigating-toxicity-in-lung-cancer-immunotherapy-challenges-and-advances-in-nano-dc321d9f12344886Pharma Surgeen2026-06-29T00:00:00.000ZNavigating toxicity in lung cancer immunotherapy: challenges and advances in Nano medicine drug deliveryhttps://www.pharmaradar360.com/article/the-intensive-outreach-programme-for-child-and-adolescent-eating-disorders-an-un-c98d54a7f64a4c3aPharma Surgeen2026-06-29T00:00:00.000ZThe intensive outreach programme for child and adolescent eating disorders: an uncontrolled case series of clinical characteristics and treatment outcomeshttps://www.pharmaradar360.com/article/adjunctive-optical-and-magnetic-stimulation-for-venous-and-mixed-etiology-leg-ul-087091683a758466Pharma Surgeen2026-06-29T00:00:00.000ZAdjunctive optical and magnetic stimulation for venous and mixed etiology leg ulcers: protocol for the NAZARÉ multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/prospective-clinical-validation-of-targeted-long-read-sequencing-for-preimplanta-d88262c33281aaeaPharma Surgeen2026-06-29T00:00:00.000ZProspective clinical validation of targeted long-read sequencing for preimplantation genetic testing of α-thalassaemiahttps://www.pharmaradar360.com/article/timing-and-clinical-burden-of-febrile-neutropenia-and-treatment-discontinuation-32cc5a4cc0a3c221Pharma Surgeen2026-06-29T00:00:00.000ZTiming and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapyhttps://www.pharmaradar360.com/article/rising-trends-in-dementia-and-psychoactive-drug-related-mortality-in-the-united-e1a1069c8ee85e44Pharma Surgeen2026-06-29T00:00:00.000ZRising trends in dementia and psychoactive drug-related mortality in the United States, 2000–2023. A retrospective analysis using CDC WONDERhttps://www.pharmaradar360.com/article/epidemiology-and-clinical-profile-of-inflammatory-bowel-disease-in-kuwait-a-nati-c734bdb7af6384e9Pharma Surgeen2026-06-29T00:00:00.000ZEpidemiology and clinical profile of inflammatory bowel disease in Kuwait: a nationwide tertiary care (SEEF-IBD) studyhttps://www.pharmaradar360.com/article/predictive-value-of-the-novel-cardiometabolic-index-for-reduced-aerobic-capacity-40ddb7dc2192baeePharma Surgeen2026-06-29T00:00:00.000ZPredictive value of the novel cardiometabolic index for reduced aerobic capacity in patients with coronary heart disease: a clinical comparative study of 378 caseshttps://www.pharmaradar360.com/article/commentary-the-clinical-activity-of-nurses-in-general-practice-c96374dd84823ee0Pharma Surgeen2026-06-29T00:00:00.000ZCommentary: The clinical activity of nurses in general practicehttps://www.pharmaradar360.com/article/correction-to-effectiveness-of-a-message-service-on-child-oral-health-practice-v-1d8caf198390e90fPharma Surgeen2026-06-29T00:00:00.000ZCorrection to “Effectiveness of a message service on child oral health practice via a social media application: A randomized controlled trial”https://www.pharmaradar360.com/article/clinical-burnout-a-diagnosis-in-search-of-validation-7bc426058fcecb0cPharma Surgeen2026-06-29T00:00:00.000Z“Clinical Burnout”: A Diagnosis in Search of Validationhttps://www.pharmaradar360.com/article/pulsatile-fxr-agonism-66db7c0b1dda49c2Pharma Surgeen2026-06-29T00:00:00.000ZPulsatile FXR agonismhttps://www.pharmaradar360.com/article/informing-sampling-design-for-lung-distribution-studies-using-a-pulmonary-popula-511cac742474990dPharma Surgeen2026-06-29T00:00:00.000ZInforming Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Modelhttps://www.pharmaradar360.com/article/bridging-solubility-stability-and-translation-advances-in-carbon-nanotube-based-c143a9ca25c8f220Pharma Surgeen2026-06-29T00:00:00.000ZBridging solubility, stability, and translation: advances in carbon nanotube–based drug delivery systemshttps://www.pharmaradar360.com/article/two-cases-of-successful-treatment-of-bleeding-esophagojejunal-varices-after-tota-c03606f4e3b2f914Pharma Surgeen2026-06-29T00:00:00.000ZTwo cases of successful treatment of bleeding esophagojejunal varices after total gastrectomy using reopenable clip hemostasishttps://www.pharmaradar360.com/article/clinical-characteristics-of-acute-pancreatitis-in-patients-with-inflammatory-bow-a85ee32f91271444Pharma Surgeen2026-06-29T00:00:00.000ZClinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japanhttps://www.pharmaradar360.com/article/preventing-post-denosumab-bone-loss-with-zoledronate-a-2-year-randomized-trial-i-099c755b169e5c3dPharma Surgeen2026-06-29T00:00:00.000ZPreventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonateshttps://www.pharmaradar360.com/article/can-t-japan-cultivate-top-tier-biotech-companies-f3eefc53297fa21bPharma Surgeen2026-06-28T23:50:16.000ZCan't Japan Cultivate Top-Tier Biotech Companies?https://www.pharmaradar360.com/article/gc-wellbeing-clinches-korea-rights-to-raziel-fat-shot-as-us-phase-3-nears-chosun-b368d50a5031ef1cPharma Surgeen2026-06-28T23:26:00.000ZGC Wellbeing clinches Korea rights to Raziel fat-shot as US phase 3 nears - CHOSUNBIZhttps://www.pharmaradar360.com/article/gc-green-cross-wellbeing-introduces-fat-dissolving-injectable-ahead-of-u-s-phase-c21612dda2254408Pharma Surgeen2026-06-28T23:19:04.000ZGC Green Cross Wellbeing Introduces Fat-Dissolving Injectable Ahead of U.S. Phase 3 Clinical Trialshttps://www.pharmaradar360.com/article/informe-country-by-country-publico-grupo-norbel-fy25-ef45a5ff0845c3abPharma Surgeen2026-06-28T22:00:00.000ZInforme Country by Country Público_Grupo Norbel FY25https://www.pharmaradar360.com/article/otro-informacion-relevante-c87ba61d8c8d81faPharma Surgeen2026-06-28T22:00:00.000ZOtro información relevantehttps://www.pharmaradar360.com/article/fda-approves-viridian-s-thyroid-eye-disease-drug-competitor-to-a-blockbuster-amg-6dc8874b1c913a3bPharma Surgeen2026-06-28T21:03:09.000ZFDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Medhttps://www.pharmaradar360.com/article/bill-aims-to-extend-cybersecurity-review-of-made-in-china-medical-devices-24a68aac26f5b553Pharma Surgeen2026-06-28T20:39:29.000ZBill Aims to Extend Cybersecurity Review of Made-in-China Medical Deviceshttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-06-28T20:37:00.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/fda-recalls-heart-and-blood-pressure-drugs-over-safety-concerns-7515d22b6c19785aPharma Surgeen2026-06-28T20:13:01.000ZFDA recalls heart and blood pressure drugs over safety concernshttps://www.pharmaradar360.com/article/bridgebio-pharma-announces-nejm-publication-and-iccbh-presentation-of-positive-p-8572bdb209fb0711Pharma Surgeen2026-06-28T20:10:00.000ZBridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasiahttps://www.pharmaradar360.com/article/bridgebio-s-achondroplasia-drug-posts-nejm-phase-3-data-9feea786f9fb44aaPharma Surgeen2026-06-28T20:00:00.000ZBridgeBio's achondroplasia drug posts NEJM Phase 3 datahttps://www.pharmaradar360.com/article/pharmaceutical-desiccant-sachets-market-growth-to-accelerate-by-2035-amid-biolog-f2b51f9362699d95Pharma Surgeen2026-06-28T19:56:22.000ZPharmaceutical Desiccant Sachets Market Growth to Accelerate by 2035 Amid Biologic Drug Expansion and Stricter Moisture Control Mandates - News and Statisticshttps://www.pharmaradar360.com/article/efzimfotase-alfa-demonstrated-improvements-in-bone-health-in-treatment-naive-ped-2738797d6b722dddPharma Surgeen2026-06-28T19:45:00.000ZEfzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trialhttps://www.pharmaradar360.com/article/top-supplements-americans-use-are-shifting-from-multivitamins-to-targeted-health-3bc218c51b6923dePharma Surgeen2026-06-28T18:15:48.000ZTop supplements Americans use are shifting from multivitamins to targeted health fixeshttps://www.pharmaradar360.com/article/viridian-s-thyroid-eye-disease-drug-wins-fda-nod-squaring-off-with-amgen-s-tepez-29b79d910565e197Pharma Surgeen2026-06-28T17:56:02.000ZViridian's thyroid eye disease drug wins FDA nod, squaring off with Amgen's Tepezzahttps://www.pharmaradar360.com/article/is-viking-therapeutics-stock-a-no-brainer-buy-below-35-a528898970a236d0Pharma Surgeen2026-06-28T17:28:15.000ZIs Viking Therapeutics Stock a No-Brainer Buy Below $35?https://www.pharmaradar360.com/article/the-overlooked-reason-why-new-drugs-take-so-long-and-the-10-trillion-fix-5b8e269c75894b7fPharma Surgeen2026-06-28T15:51:46.000ZThe overlooked reason why new drugs take so long—and the $10 trillion fixhttps://www.pharmaradar360.com/article/nearly-1-million-heart-and-kidney-medication-bottles-recalled-in-major-fda-alert-0639e5841d0e3cc7Pharma Surgeen2026-06-28T15:42:23.000ZNearly 1 Million Heart And Kidney Medication Bottles Recalled In Major FDA Alerthttps://www.pharmaradar360.com/article/medicine-security-is-national-security-psgh-demands-70-local-drug-production-7f4305bad6d15033Pharma Surgeen2026-06-28T15:20:57.000Z“Medicine Security Is National Security”: PSGH Demands 70% Local Drug Productionhttps://www.pharmaradar360.com/article/teva-pharmaceutical-s-innovative-shift-continues-with-ecopipam-addition-nyse-tev-cff52243bf702955Pharma Surgeen2026-06-28T15:01:39.000ZTeva Pharmaceutical's Innovative Shift Continues With Ecopipam Addition (NYSE:TEVA)https://www.pharmaradar360.com/article/maharashtra-fda-busts-rs-52-lakh-expired-food-racket-fir-filed-against-amazon-wa-a7d0df7c51761094Pharma Surgeen2026-06-28T14:45:00.000ZMaharashtra FDA busts Rs 52-lakh expired food racket; FIR filed against Amazon warehouse officialshttps://www.pharmaradar360.com/article/psilocybin-could-become-the-first-fda-approved-psychedelic-therapy-within-months-e9bbe42c6f1435cePharma Surgeen2026-06-28T14:30:00.000ZPsilocybin Could Become the First FDA-Approved Psychedelic Therapy Within Months — Here Is What Patients Need to Knowhttps://www.pharmaradar360.com/article/fda-approves-first-single-dose-generic-treatment-for-influenza-cc1b21567fa322ebPharma Surgeen2026-06-28T14:30:00.000ZFDA approves first single-dose generic treatment for influenzahttps://www.pharmaradar360.com/article/10-best-biotech-stocks-to-buy-according-to-analysts-7a8f0a1dfa669d3cPharma Surgeen2026-06-28T14:21:43.000Z10 Best Biotech Stocks to Buy According to Analystshttps://www.pharmaradar360.com/article/5-best-biotech-stocks-to-buy-according-to-analysts-a9d7e0016abac546Pharma Surgeen2026-06-28T14:21:43.000Z5 Best Biotech Stocks to Buy According to Analystshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-vytrus-biotech-sa-bme-vyt-2971f32699c8b8fdPharma Surgeen2026-06-28T14:20:14.000ZPrice to earnings forward of Vytrus Biotech SA – BME:VYThttps://www.pharmaradar360.com/article/russian-strike-damages-kyiv-pharmaceutical-plant-during-attack-f1a7ea22a6702b18Pharma Surgeen2026-06-28T14:02:53.000ZRussian Strike Damages Kyiv Pharmaceutical Plant During Attackhttps://www.pharmaradar360.com/article/hackensack-meridian-health-joins-phase-3-trial-of-pfizer-s-investigational-c-dif-7ff0c6a79882ef3aPharma Surgeen2026-06-28T13:39:33.000ZHackensack Meridian Health Joins Phase 3 Trial of Pfizer’s Investigational C difficile Vaccinehttps://www.pharmaradar360.com/article/russian-strike-damaged-darnytsia-pharmaceutical-plant-in-kyiv-no-casualties-685a1547424654e7Pharma Surgeen2026-06-28T13:33:20.000ZRussian strike damaged Darnytsia pharmaceutical plant in Kyiv, no casualtieshttps://www.pharmaradar360.com/article/fda-approves-besremi-pen-for-self-administration-in-polycythemia-vera-8ce2553e3d67b636Pharma Surgeen2026-06-28T13:03:33.000ZFDA Approves BESREMi Pen for Self-Administration in Polycythemia Verahttps://www.pharmaradar360.com/article/generic-enzalutamide-tablets-granted-tentative-fda-approval-for-prostate-cancer-af75013723ae327fPharma Surgeen2026-06-28T12:50:41.000ZGeneric Enzalutamide Tablets Granted Tentative FDA Approval for Prostate Cancerhttps://www.pharmaradar360.com/article/gas-chromatography-systems-market-forecast-points-higher-toward-2035-driven-by-p-09bb7beb506d669cPharma Surgeen2026-06-28T12:23:05.000ZGas Chromatography Systems Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Quality Mandateshttps://www.pharmaradar360.com/article/fda-leadership-s-blind-spots-lead-to-a-surge-in-medical-device-and-drug-recalls-a02b6651abdf64c8Pharma Surgeen2026-06-28T12:11:29.000ZFDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recallshttps://www.pharmaradar360.com/article/fda-conducts-surprise-inspection-at-parbhani-girls-hostel-kitchen-checks-food-sa-ba8a31b65baa50cePharma Surgeen2026-06-28T10:37:47.000ZFDA Conducts Surprise Inspection At Parbhani Girls Hostel Kitchen, Checks Food Safetyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-veraxa-biotech-ag-nasdaq-vrxaw-e56ce4f87cc7132dPharma Surgeen2026-06-28T10:36:26.000ZPrice to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAWhttps://www.pharmaradar360.com/article/phase-3-trident-trial-misses-survival-end-point-in-glioblastoma-a39cdd0fbac6be82Pharma Surgeen2026-06-28T10:09:11.000ZPhase 3 TRIDENT Trial Misses Survival End Point in Glioblastomahttps://www.pharmaradar360.com/article/russians-hit-pharmaceutical-manufacturer-darnytsia-in-kyiv-557095a7bb5231fdPharma Surgeen2026-06-28T10:00:00.000ZRussians hit pharmaceutical manufacturer Darnytsia in Kyivhttps://www.pharmaradar360.com/article/a-cfo-departure-a-clinical-miss-a-43-billion-question-mark-should-you-throw-in-t-b0290043f6d63aabPharma Surgeen2026-06-28T09:30:00.000ZA CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-cf640c7094a0a6e3Pharma Surgeen2026-06-28T09:26:35.000ZEnterprise value to revenue forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-ultragenyx-pharmaceutical-inc-nasdaq-rare-6c5ed099781b6849Pharma Surgeen2026-06-28T09:21:37.000ZEnterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RAREhttps://www.pharmaradar360.com/article/phase-3-reconnect-trial-zyn002-fails-to-meet-primary-endpoint-in-fragile-x-syndr-99aa8afa95856b7ePharma Surgeen2026-06-28T08:51:44.000ZPhase 3 RECONNECT Trial: ZYN002 Fails to Meet Primary Endpoint in Fragile X Syndrome Populationhttps://www.pharmaradar360.com/article/a-cfo-departure-a-clinical-miss-a-43-billion-question-mark-should-you-throw-in-t-070a6f540a2970b2Pharma Surgeen2026-06-28T08:50:00.000ZA CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?https://www.pharmaradar360.com/article/price-to-book-forward-of-hangzhou-alltest-biotech-co-ltd-class-a-sse-688606-ddf2ea1bda90bda1Pharma Surgeen2026-06-28T08:41:05.000ZPrice to book forward of Hangzhou Alltest Biotech Co., Ltd. Class A – SSE:688606https://www.pharmaradar360.com/article/is-viking-therapeutics-stock-a-no-brainer-buy-below-35-db263bf6683fa0c3Pharma Surgeen2026-06-28T07:35:46.000ZIs Viking Therapeutics stock a no-brainer buy below $35?https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kyongbo-pharmaceutical-co-ltd-krx-214390-1a54e593f213e2ffPharma Surgeen2026-06-28T06:54:37.000ZEnterprise value to revenue forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390https://www.pharmaradar360.com/article/price-to-earnings-forward-of-kyongbo-pharmaceutical-co-ltd-krx-214390-5aa45583984bfac5Pharma Surgeen2026-06-28T06:51:10.000ZPrice to earnings forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jilin-aodong-pharmaceutical-group-co-ltd-cla-9c8bb0fca355dea0Pharma Surgeen2026-06-28T06:30:33.000ZEnterprise value to EBIT forward of Jilin Aodong Pharmaceutical Group Co., Ltd. Class A – SZSE:000623https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kyongbo-pharmaceutical-co-ltd-krx-214390-257efcdc6a05921ePharma Surgeen2026-06-28T06:30:30.000ZEnterprise value to EBIT forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390https://www.pharmaradar360.com/article/price-to-earnings-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-cabb755cc67f2743Pharma Surgeen2026-06-28T06:19:03.000ZPrice to earnings forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/price-to-earnings-forward-of-towa-pharmaceutical-co-ltd-tse-4553-ef0419de45c3c28aPharma Surgeen2026-06-28T06:15:00.000ZPrice to earnings forward of Towa Pharmaceutical Co., Ltd. – TSE:4553https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jilin-aodong-pharmaceutical-group-co-ltd-c-d088ea3b9eb49077Pharma Surgeen2026-06-28T06:04:21.000ZEnterprise value to EBITDA forward of Jilin Aodong Pharmaceutical Group Co., Ltd. Class A – SZSE:000623https://www.pharmaradar360.com/article/inside-the-high-stakes-gamble-to-revive-tanked-biotech-opthea-56d08228815244e0Pharma Surgeen2026-06-28T06:00:00.000ZInside the high-stakes gamble to revive tanked biotech Optheahttps://www.pharmaradar360.com/article/price-to-sales-forward-of-owc-pharmaceutical-research-corp-otc-owcp-30a46862da066361Pharma Surgeen2026-06-28T05:58:34.000ZPrice to sales forward of OWC PHARMACEUTICAL RESEARCH CORP – OTC:OWCPhttps://www.pharmaradar360.com/article/price-to-book-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-c51b0bb77d3685baPharma Surgeen2026-06-28T05:52:51.000ZPrice to book forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-fefd48f3ecebedb9Pharma Surgeen2026-06-28T05:46:17.000ZEnterprise value to EBIT forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/grce-stock-plunges-45-after-fda-rejects-brain-injury-drug-company-says-concerns-731b4850bee4f1bePharma Surgeen2026-06-28T05:34:23.000ZGRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixablehttps://www.pharmaradar360.com/article/number-of-shareholders-of-zhejiang-huahai-pharmaceutical-co-ltd-class-a-sse-6005-0f3f463ba2acd26cPharma Surgeen2026-06-28T05:31:13.000ZNumber of shareholders of Zhejiang Huahai Pharmaceutical Co., Ltd. Class A – SSE:600521https://www.pharmaradar360.com/article/price-to-sales-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-636a9bc1a69b4d94Pharma Surgeen2026-06-28T05:28:43.000ZPrice to sales forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/why-is-the-us-targeting-germany-s-drug-industry-751043cbd7a52576Pharma Surgeen2026-06-28T05:17:55.000ZWhy is the US targeting Germany's drug industry?https://www.pharmaradar360.com/article/sls-stock-rallies-ahead-of-aml-trial-readout-pharma-bro-martin-shkreli-says-he-s-4fa9eb9f47644bd1Pharma Surgeen2026-06-28T05:16:36.000ZSLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Failhttps://www.pharmaradar360.com/article/dw-news-people-living-in-the-us-pay-up-to-three-times-more-for-medicine-than-eur-50fc228b9e246f98Pharma Surgeen2026-06-28T05:00:23.000ZDW News. . People living in the US pay up to three times more for medicine than Europeans. Donald Trump says Europe is to blame — but the reality is more complicated. #dwbusinesshttps://www.pharmaradar360.com/article/vrdn-stock-jumps-6-after-hours-as-viridian-wins-first-fda-approval-9dc28d478c8f55d7Pharma Surgeen2026-06-28T04:44:54.000ZVRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approvalhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hwail-pharmaceutical-co-ltd-krx-061250-1f0312a0ad116c68Pharma Surgeen2026-06-28T04:43:53.000ZEnterprise value to EBITDA forward of Hwail Pharmaceutical Co., Ltd. – KRX:061250https://www.pharmaradar360.com/article/brivaracetam-market-restructuring-competition-focuses-on-sales-power-and-early-m-125067c7780faed4Pharma Surgeen2026-06-28T04:40:00.000ZBrivaracetam Market Restructuring: Competition Focuses on Sales Power and Early Market Entryhttps://www.pharmaradar360.com/article/legend-biotech-legn-reports-lb2501-progress-is-the-stock-still-cheap-cc070817fd833036Pharma Surgeen2026-06-28T04:21:40.000ZLegend Biotech (LEGN) Reports LB2501 Progress, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/fda-says-yes-to-viridian-s-lumvoa-in-ted-6cbd81e1dff92b2ePharma Surgeen2026-06-28T04:00:00.000ZFDA says yes to Viridian’s Lumvoa in TEDhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-huahai-pharmaceutical-co-ltd-class-c99879ce088b3a7bPharma Surgeen2026-06-28T03:36:44.000ZEnterprise value to EBIT forward of Zhejiang Huahai Pharmaceutical Co., Ltd. Class A – SSE:600521https://www.pharmaradar360.com/article/price-to-sales-forward-of-zhejiang-huahai-pharmaceutical-co-ltd-class-a-sse-6005-7eb150c9246663cfPharma Surgeen2026-06-28T03:11:14.000ZPrice to sales forward of Zhejiang Huahai Pharmaceutical Co., Ltd. Class A – SSE:600521https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-trinity-biotech-plc-nasdaq-trib-5b6ff068dc9c67d5Pharma Surgeen2026-06-28T02:37:37.000ZEnterprise value to EBITDA forward of Trinity Biotech plc – NASDAQ:TRIBhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-trinity-biotech-plc-nasdaq-trib-04850e62efd2b04ePharma Surgeen2026-06-28T02:28:14.000ZEnterprise value to EBIT forward of Trinity Biotech plc – NASDAQ:TRIBhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-5d6684b7cd4d6536Pharma Surgeen2026-06-28T02:20:41.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/help-stock-crashes-on-anxiety-trial-results-but-here-s-why-jefferies-sees-up-to-145d42874ac0b13fPharma Surgeen2026-06-28T02:02:43.000ZHELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upsidehttps://www.pharmaradar360.com/article/why-is-cing-stock-jumping-over-4-in-overnight-trading-5af302c03e4c000dPharma Surgeen2026-06-28T01:10:18.000ZWhy Is CING Stock Jumping Over 4% In Overnight Trading?https://www.pharmaradar360.com/article/this-little-known-biotech-just-delivered-a-bigger-ipo-pop-than-spacex-and-regene-5091cadf9f1dbd6ePharma Surgeen2026-06-28T01:00:00.000ZThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-zhejiang-jiuzhou-pharmaceutical-co-ltd-class-a-sse-603-bddafb76d7c93c87Pharma Surgeen2026-06-28T00:53:30.000ZPrice to sales forward of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A – SSE:603456https://www.pharmaradar360.com/article/shara-avis-pecoraro-biotech-is-global-but-we-all-have-the-same-goal-help-patient-7d24df42456de30dPharma Surgeen2026-06-28T00:51:35.000ZShara Avis Pecoraro: Biotech Is Global, but We All Have the Same Goal – Help Patientshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-jiuzhou-pharmaceutical-co-ltd-class-a-sse-93714fa25ba86ce2Pharma Surgeen2026-06-28T00:51:01.000ZPrice to earnings forward of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A – SSE:603456https://www.pharmaradar360.com/article/this-little-known-biotech-just-delivered-a-bigger-ipo-pop-than-spacex-and-regene-857888f559f77a84Pharma Surgeen2026-06-28T00:35:23.000ZThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-06-28T00:34:25.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/this-little-known-biotech-just-delivered-a-bigger-ipo-pop-than-spacex-and-regene-41e5b9f830917019Pharma Surgeen2026-06-28T00:20:00.000ZThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedhttps://www.pharmaradar360.com/article/development-and-clinical-deployment-of-the-systematic-urgent-team-response-in-th-e3c668d7226cb55aPharma Surgeen2026-06-28T00:00:00.000ZDevelopment and Clinical Deployment of the Systematic Urgent Team Response in the Operating Room (SUTO) Protocol for Intraoperative Massive Hemorrhage: A Technical Reporthttps://www.pharmaradar360.com/article/legal-analysis-of-artificial-intelligence-regulation-as-a-clinical-decision-supp-456f546601c57fa5Pharma Surgeen2026-06-28T00:00:00.000ZLEGAL ANALYSIS OF ARTIFICIAL INTELLIGENCE REGULATION AS A CLINICAL DECISION SUPPORT SYSTEM IN INDONESIAN HOSPITALS: CHALLENGES, ACCOUNTABILITY, AND REGULATORY REFORMhttps://www.pharmaradar360.com/article/improving-student-learning-at-sman-2-regarding-the-general-ledger-and-trial-bala-fd12ff495929a32ePharma Surgeen2026-06-28T00:00:00.000ZImproving Student Learning at SMAN 2 Regarding the General Ledger and Trial Balance Worksheetshttps://www.pharmaradar360.com/article/infection-prevention-and-control-systems-in-nigerian-tertiary-hospitals-a-system-1884395951293648Pharma Surgeen2026-06-28T00:00:00.000ZInfection Prevention and Control Systems in Nigerian Tertiary Hospitals: A Systematic Review Study of Policy Implementation and Clinical Outcomeshttps://www.pharmaradar360.com/article/analisis-faktor-yang-mempengaruhi-kepatuhan-implementasi-cara-distribusi-obat-ya-6b848dd50db7a6e1Pharma Surgeen2026-06-28T00:00:00.000ZANALISIS FAKTOR YANG MEMPENGARUHI KEPATUHAN IMPLEMENTASI CARA DISTRIBUSI OBAT YANG BAIK (CDOB) PADA PEDAGANG BESAR FARMASI DI KOTA CIREBONhttps://www.pharmaradar360.com/article/effects-of-a-transformative-learning-theory-based-health-literacy-enhancement-pr-97e524fa07ffeeb1Pharma Surgeen2026-06-28T00:00:00.000ZEffects of a transformative learning theory-based health literacy enhancement program on self-management behaviors and blood pressure in adults with uncontrolled hypertension in Thailand: A cluster randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-medagogy-based-health-literacy-enhancement-on-self-management-behavio-0c8a34f814a6663cPharma Surgeen2026-06-28T00:00:00.000ZEffects of medagogy-based health literacy enhancement on self-management behaviors and functional capacity among older persons with chronic heart failure: A randomized controlled trialhttps://www.pharmaradar360.com/article/the-effect-of-a-self-management-program-through-a-mobile-application-on-lipid-pr-92d49b73112c79eaPharma Surgeen2026-06-28T00:00:00.000ZThe effect of a self-management program through a mobile application on lipid profile among persons with coronary artery disease: A randomized controlled trial study in Thailandhttps://www.pharmaradar360.com/article/effectiveness-of-lay-counselor-delivered-intervention-for-trauma-related-symptom-bdb3d5a51e7811bfPharma Surgeen2026-06-28T00:00:00.000ZEffectiveness of lay counselor-delivered intervention for trauma-related symptoms in conflict- affected populations: a cluster randomized trial in Iraqhttps://www.pharmaradar360.com/article/malaria-prevalence-and-molecular-markers-of-plasmodium-falciparum-antimalarial-d-416b9b6359170351Pharma Surgeen2026-06-28T00:00:00.000ZMalaria prevalence and molecular markers of Plasmodium falciparum antimalarial drug resistance among mobile populations in malaria-endemic countries: A systematic review and meta-analysishttps://www.pharmaradar360.com/article/inproteamed-interprofessional-clinical-assessment-in-the-emergency-department-a-8f2cd4b3c586b109Pharma Surgeen2026-06-28T00:00:00.000ZinproTeamED - Interprofessional clinical assessment in the emergency department: A qualitative analysishttps://www.pharmaradar360.com/article/initial-outpatient-clinical-characteristics-associated-with-subsequent-conversio-6bb9446ddc94f8d5Pharma Surgeen2026-06-28T00:00:00.000ZInitial outpatient clinical characteristics associated with subsequent conversion from mild cognitive impairment to dementia: a retrospective exploratory studyhttps://www.pharmaradar360.com/article/application-of-propensity-score-methods-to-address-missing-data-in-a-trial-on-th-1a18fb6aa4367946Pharma Surgeen2026-06-28T00:00:00.000ZApplication of Propensity Score Methods to Address Missing Data in a Trial on the Effect of Energy Protein Supplementation Among Pulmonary TB-HIV Patients in Mwanza, Tanzaniahttps://www.pharmaradar360.com/article/reclassification-of-variants-of-uncertain-significance-in-brca1-brca2-and-palb2-79129580d983ba15Pharma Surgeen2026-06-28T00:00:00.000ZReclassification of Variants of Uncertain Significance in BRCA1, BRCA2, and PALB2: Implications for Clinical Decision-Making in Breast Cancerhttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-in-dry-eye-disease-secondary-to-chroni-4e0cd4d357805567Pharma Surgeen2026-06-28T00:00:00.000ZClinical characteristics and risk factors in dry eye disease secondary to chronic graft-versus-host: A Comparative Cross-Sectional Studyhttps://www.pharmaradar360.com/article/combined-use-of-etomidate-and-propofol-reduce-the-duration-of-apnea-vs-propofol-9e49894d7d647c11Pharma Surgeen2026-06-28T00:00:00.000ZCombined use of etomidate and propofol reduce the duration of apnea vs propofol along in patients undergoing hysteroscopy: a randomised double-blind trialhttps://www.pharmaradar360.com/article/distribution-of-citalopram-enantiomers-following-medication-with-racemic-citalop-8bf6cc8d9a92afa3Pharma Surgeen2026-06-28T00:00:00.000ZDistribution of citalopram enantiomers following medication with racemic citalopram - a naturalistic therapeutic drug monitoring studyhttps://www.pharmaradar360.com/article/effectiveness-of-a-novel-mobile-health-application-in-educating-first-time-compl-162c1bae1b993dacPharma Surgeen2026-06-28T00:00:00.000ZEffectiveness of a novel mobile health application in educating first time complete denture wearers: a prospective clinical studyhttps://www.pharmaradar360.com/article/mri-radiomics-for-the-prediction-of-histologic-grade-in-bladder-cancer-533ee201da9bd214Pharma Surgeen2026-06-28T00:00:00.000ZMRI radiomics for the prediction of histologic grade in bladder cancerhttps://www.pharmaradar360.com/article/antimicrobial-resistance-surveillance-of-clinical-isolates-collected-from-paedia-0799bb0ec674f2a8Pharma Surgeen2026-06-28T00:00:00.000ZAntimicrobial resistance surveillance of clinical isolates collected from paediatric and adult patients of intensive care units in China from 2017 to 2022https://www.pharmaradar360.com/article/barbed-versus-traditional-sutures-in-primary-total-knee-arthroplasty-systematic-50e1f4b274645731Pharma Surgeen2026-06-28T00:00:00.000ZBarbed versus traditional sutures in primary total knee arthroplasty: systematic review and meta-analysis of clinical outcomes and wound-related complicationshttps://www.pharmaradar360.com/article/clinical-outcomes-after-the-implementation-of-a-patient-centered-care-program-ap-65d6ecf64ed3a267Pharma Surgeen2026-06-28T00:00:00.000ZClinical outcomes after the implementation of a patient-centered care program applied to newly admitted people with HIV in Mexico City: a retrospective cohort studyhttps://www.pharmaradar360.com/article/integrating-lipometabolic-and-adiposity-indices-to-enhance-risk-stratification-f-1365657d3ef9cffdPharma Surgeen2026-06-28T00:00:00.000ZIntegrating lipometabolic and adiposity indices to enhance risk stratification for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: clinical utility and interplay between triglyceride-glucose body mass index and low-density lipoprotein cholesterolhttps://www.pharmaradar360.com/article/severe-acute-hepatitis-induced-by-combined-rosuvastatin-and-ticagrelor-therapy-p-06ae7d8cbb742140Pharma Surgeen2026-06-28T00:00:00.000ZSevere Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosishttps://www.pharmaradar360.com/article/can-multilingual-environments-promote-scalable-edtech-evidence-from-a-randomized-3d814ac2dcd1772fPharma Surgeen2026-06-28T00:00:00.000ZCan Multilingual Environments Promote Scalable EdTech? Evidence from a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/a-large-scale-randomized-control-trial-showing-llm-generated-feedback-helps-low-3eb5fa632aa13e45Pharma Surgeen2026-06-28T00:00:00.000ZA Large Scale Randomized Control Trial Showing LLM Generated Feedback Helps Low-Knowledge Middle School Math Students with Short-Term Learninghttps://www.pharmaradar360.com/article/letter-assessing-pruritus-efficacy-with-peroxisome-proliferator-activated-recept-7343187ce70aba6bPharma Surgeen2026-06-28T00:00:00.000ZLetter: Assessing Pruritus Efficacy With Peroxisome Proliferator‐Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidencehttps://www.pharmaradar360.com/article/effects-of-concurrent-transcranial-direct-current-stimulation-and-robotic-lower-cd500e8ff0caf718Pharma Surgeen2026-06-28T00:00:00.000ZEffects of concurrent transcranial direct current stimulation and robotic lower-limb training on motor recovery after stroke: a randomized sham-controlled trialhttps://www.pharmaradar360.com/article/spontaneous-regression-of-colorectal-liver-metastasis-with-coexisting-igg4-rich-a68a241ac893c283Pharma Surgeen2026-06-28T00:00:00.000ZSpontaneous regression of colorectal liver metastasis with coexisting IgG4-rich inflammatory pseudotumor-like changes: a case reporthttps://www.pharmaradar360.com/article/a-case-of-small-pancreatic-neuroendocrine-tumor-of-less-than-10-mm-showing-metas-2fe0ccfaf8532014Pharma Surgeen2026-06-28T00:00:00.000ZA case of small pancreatic neuroendocrine tumor of less than 10 mm showing metastasis to multiple organshttps://www.pharmaradar360.com/article/association-between-mental-health-of-patients-with-work-related-injury-and-their-8a0ce07bcb1102d3Pharma Surgeen2026-06-28T00:00:00.000ZAssociation Between Mental Health of Patients with Work-Related Injury and Their Compensation Claim Status: Exploratory Findings from the IMPRovE Trialhttps://www.pharmaradar360.com/article/pathogens-in-the-bay-environmental-staphylococcus-saprophyticus-strains-mirror-c-1f794e165cd35be5Pharma Surgeen2026-06-28T00:00:00.000ZPathogens in the bay: environmental Staphylococcus saprophyticus strains mirror clinical counterparts in virulence, biofilm formation, antimicrobial resistance, pathogenicity, and phage susceptibilityhttps://www.pharmaradar360.com/article/beyond-the-jak2-mutation-the-inflammasome-clonal-stability-and-the-thrombotic-ni-10ac9b4729043f61Pharma Surgeen2026-06-28T00:00:00.000ZBeyond the JAK2 mutation: The inflammasome, clonal stability, and the thrombotic niche in myeloproliferative neoplasmshttps://www.pharmaradar360.com/article/harnessing-the-gut-microbiome-for-improved-immune-checkpoint-inhibition-in-color-d9264b774896dbd5Pharma Surgeen2026-06-28T00:00:00.000ZHarnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Reviewhttps://www.pharmaradar360.com/article/social-appearance-anxiety-and-its-associations-with-anxiety-depressive-symptoms-492e5879a72e6d2bPharma Surgeen2026-06-28T00:00:00.000ZSocial appearance anxiety and its associations with anxiety, depressive symptoms, and health-related quality of life in systemic sclerosis: a cross-sectional studyhttps://www.pharmaradar360.com/article/enhancing-the-treat-to-target-approach-of-inflammatory-arthritis-with-purposeful-b7569fcb66d3ce4ePharma Surgeen2026-06-28T00:00:00.000ZEnhancing the treat-to-target approach of inflammatory arthritis with purposeful shared decision-making: results of a randomized controlled trialhttps://www.pharmaradar360.com/article/pseudomonas-aeruginosa-st4936-with-extensive-antibacterial-drug-resistance-and-v-534590599132ad3aPharma Surgeen2026-06-28T00:00:00.000ZPseudomonas aeruginosa ST4936 with extensive antibacterial drug resistance and virulence determinants from ureteral stent biofilms: whole-genome insightshttps://www.pharmaradar360.com/article/electrochemical-detection-of-heavy-metal-pb-ions-and-pharmaceutical-waste-ciprof-85e31dd1a6243618Pharma Surgeen2026-06-28T00:00:00.000ZElectrochemical Detection of Heavy Metal (Pb Ions) and Pharmaceutical Waste (Ciprofloxacin) in Very Low Concentration Using β‐NaFeO ₂https://www.pharmaradar360.com/article/other-titles-from-iste-in-computer-engineering-6b30f6bf78c6bcc4Pharma Surgeen2026-06-28T00:00:00.000ZOther titles from ISTE in Computer Engineeringhttps://www.pharmaradar360.com/article/index-d8134c5d8b402c02Pharma Surgeen2026-06-28T00:00:00.000ZIndexhttps://www.pharmaradar360.com/article/dynamic-condylar-screw-versus-long-pfn-in-subtrochanteric-fractures-c4d3e917fb42553bPharma Surgeen2026-06-28T00:00:00.000ZDynamic Condylar Screw Versus Long PFN in Subtrochanteric Fractureshttps://www.pharmaradar360.com/article/ai-based-functional-outcome-comparison-of-nails-in-unstable-intertrochanteric-fe-437e9789e55e386bPharma Surgeen2026-06-28T00:00:00.000ZAI‐Based Functional Outcome Comparison of Nails in Unstable Intertrochanteric Femur Fracturehttps://www.pharmaradar360.com/article/alpha-blockers-in-cervical-radiculopathy-54c266677f4a9d53Pharma Surgeen2026-06-28T00:00:00.000ZAlpha‐Blockers in Cervical Radiculopathyhttps://www.pharmaradar360.com/article/fracture-healing-after-cephalomedullary-nailing-with-zoledronic-acid-57bb15a5c7f84599Pharma Surgeen2026-06-28T00:00:00.000ZFracture Healing After Cephalomedullary Nailing with Zoledronic Acidhttps://www.pharmaradar360.com/article/rigid-versus-hybrid-fixation-in-both-bone-forearm-fractures-e9c026013221b155Pharma Surgeen2026-06-28T00:00:00.000ZRigid Versus Hybrid Fixation in Both‐Bone Forearm Fractureshttps://www.pharmaradar360.com/article/designing-nanobots-for-targeted-drug-delivery-and-the-application-of-nanotechnol-d7bdf3506b92cab9Pharma Surgeen2026-06-28T00:00:00.000ZDesigning Nanobots for Targeted Drug Delivery and the Application of Nanotechnology in Modern Medical Advancementshttps://www.pharmaradar360.com/article/ai-driven-drug-discovery-and-personalized-medicine-in-cancer-1d00dbc1d54429dbPharma Surgeen2026-06-28T00:00:00.000ZAI‐Driven Drug Discovery and Personalized Medicine in Cancerhttps://www.pharmaradar360.com/article/heterocyclic-compound-having-herbicides-activity-070e9fe41f7d9380Pharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compound Having Herbicides Activityhttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-anticonvulsants-antipyretics-antiallergic-agents-and-a-da07d2fefca6404cPharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Anticonvulsants, Antipyretics, Antiallergic Agents, and Antileprosy Agentshttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-anti-inflammatory-agents-fb4bf96a6338c552Pharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Anti‐Inflammatory Agents